missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Tocris Bioscience™ JNJ 1013

Description
JNJ 1013 is a potent interleukin 1 receptor associated kinase 1 (IRAK1) PROTAC™ Degrader (DC50 = 3 nM; Dmax = 96%). In ABC DLBCL cell lines with MyD88 L265P mutation, JNJ 1013 potently inhibits IRAK1 downstream signaling pathways, induces apoptosis, and shows strong anti-proliferative effects. PROTAC™ is a registered trademark of Arvinas Operations, Inc., and is used under license.
Specifications
Specifications
| Chemical Name or Material | N-(4-(4-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)piperidin-1-yl)-2-methoxyphenyl)-6-(1H-pyrazol-5-yl)picolinamide |
| CAS | 2597343-08-1 |
| Quantity | 5 mg |
| Target | Active Degraders |
| Molecular Formula | C46H55N9O7S |
| Purity | 98% |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?